Journal of Nutritional Oncology最新文献_第4页

The Significant Contribution of LINC00673 Rs11655237 C > T Polymorphism to Cancer Susceptibility in Chinese Population: A Meta-analysis of The Current Literature LINC00673 Rs11655237 C > T多态性对中国人群癌症易感性的显著贡献:对当前文献的荟萃分析

Journal of Nutritional Oncology Pub Date : 2021-05-15 DOI: 10.34175/jno202102006

Xuejiao Guan, Peng Du, Yong Li, Qingfeng Xiao, J. Tan, Xingjian Zhang

{"title":"The Significant Contribution of LINC00673 Rs11655237 C > T Polymorphism to Cancer Susceptibility in Chinese Population: A Meta-analysis of The Current Literature","authors":"Xuejiao Guan, Peng Du, Yong Li, Qingfeng Xiao, J. Tan, Xingjian Zhang","doi":"10.34175/jno202102006","DOIUrl":"https://doi.org/10.34175/jno202102006","url":null,"abstract":"Abstract: Objective Considerable studies exploring the relation of rs11655237 C > T polymorphism in the LINC00673 gene with cancer susceptibility have obtained debatable results. This meta-analysis aims to accurately assess this association. Methods Relevant studies with an updated date of April 20, 2021, were extensively searched from Embase, PubMed, Web of Science, Google Scholar, Medline, CNKI, and Chinese Wanfang databases. The strength of association was estimated by odds ratios (ORs) and 95% confidence intervals (CIs). Results A total of 8 articles involving 7,893 cases and 12,446 controls were ultimately selected in this analysis. Summary results revealed a significantly enhanced risk of cancer was related to LINC00673 rs11655237 C > T polymorphism for the allele model (OR = 1.22, 95% CI = 1.09-1.36), homozygote model (OR = 1.47, 95% CI = 1.30-1.67), heterozygote model (OR = 1.21, 95% CI = 1.14-1.29), dominant model (OR = 1.25, 95% CI = 1.18-1.32), and recessive model (OR = 1.26, 95% CI = 1.12-1.43). Moreover, subgroup analysis by cancer type showed LINC00673 rs11655237 C > T polymorphism contributed to the increased risk of neuroblastoma in the heterozygote, homozygote, dominant and recessive models. Conclusion The present meta-analysis indicates that LINC00673 rs11655237 C > T polymorphism is related to increased cancer susceptibility in the Chinese population. It may be a potential predictive biomarker of cancer risk.","PeriodicalId":64349,"journal":{"name":"Journal of Nutritional Oncology","volume":"81 11","pages":"90 - 100"},"PeriodicalIF":0.0,"publicationDate":"2021-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41284513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Decreased Average Albumin-to-Globulin Ratio During Radiotherapy Worsens the Prognosis of Esophageal Squamous Cell Carcinoma: Implications for Nutritional Management 放疗期间白蛋白与球蛋白平均比值降低恶化食管鳞状细胞癌的预后:营养管理的意义

Journal of Nutritional Oncology Pub Date : 2021-05-15 DOI: 10.34175/jno202102003

Fen Cai, X. Zhang, Xiao Ling Wu, T. Zhuang, Lei Huang, Yiyao Tu, Yuanzhi Lu, Minglei Jiang, Qing-Ying Zhang, Yan Lin, Chang-chun Ma

{"title":"Decreased Average Albumin-to-Globulin Ratio During Radiotherapy Worsens the Prognosis of Esophageal Squamous Cell Carcinoma: Implications for Nutritional Management","authors":"Fen Cai, X. Zhang, Xiao Ling Wu, T. Zhuang, Lei Huang, Yiyao Tu, Yuanzhi Lu, Minglei Jiang, Qing-Ying Zhang, Yan Lin, Chang-chun Ma","doi":"10.34175/jno202102003","DOIUrl":"https://doi.org/10.34175/jno202102003","url":null,"abstract":"Abstract: Objective Malnutrition and cachexia are common in esophageal squamous cell carcinoma (ESCC) patients undergoing radiotherapy. This study evaluated how malnutrition- and cachexia-related indicators, including the albumin-to-globulin ratio (AGR), and their changes during radiotherapy predict the treatment outcomes. Methods We reviewed a total of 172 ESCC patients receiving radiotherapy (as a primary cohort) and performed a Cox regression analysis on potential prognostic factors, including the AGR, as well as the TNM stage and concomitant chemotherapy. A subsequent receiver operating characteristics (ROC) curve and Kaplan Meier survival analysis was performed for ESCC patients stratified by the average AGR cut-off point. Results In addition to the well-documented factors (i.e. TNM stage and concomitant chemotherapy), the average AGR was a significant prognostic factor for ESCC patients receiving radiotherapy. By plotting the ROC curve of the average AGR with regard to the ESCC prognosis, we obtained cut-off points for the overall patients (cut-off point: 1.5, AUC: 0.636), for patients with stage II/III disease (cut-off point: 1.5, AUC: 0.611), and for patients with stage IV disease (cut-off point: 1.84, AUC: 0.900). The ESCC patients with higher average AGR had a significantly more favorable OS compared with those with a lower average AGR. Notably, ESCC patients who had an increasing ΔAGR during radiotherapy had a considerably more favorable OS compared with those with a decreasing ΔAGR. All of these findings were reproducible in the validation cohort. Conclusion A lower average AGR is indicative of a poorer prognosis for ESCC patients following radiotherapy. Improving the nutritional status and preventing or ameliorating cachexia might contribute to improving the prognosis of ESCC patients.","PeriodicalId":64349,"journal":{"name":"Journal of Nutritional Oncology","volume":"6 1","pages":"64 - 73"},"PeriodicalIF":0.0,"publicationDate":"2021-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42340964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of 1q21 Gain on the Prognosis of Multiple Myeloma 1q21增益在多发性骨髓瘤预后中的作用

Journal of Nutritional Oncology Pub Date : 2021-05-15 DOI: 10.34175/jno202102001

D. Xing, Jin Wang, Zhi-gang Zhao

{"title":"The Role of 1q21 Gain on the Prognosis of Multiple Myeloma","authors":"D. Xing, Jin Wang, Zhi-gang Zhao","doi":"10.34175/jno202102001","DOIUrl":"https://doi.org/10.34175/jno202102001","url":null,"abstract":"Abstract: Multiple myeloma (MM) is a clonal expansion of malignant plasma cells, and comprises approximately 10% of hematologic malignancies. Although various therapeutic agents and strategies, such as immunomodulatory agents, proteasome inhibitors, monoclonal antibodies and hematopoietic stem cell transplantation (HSCT) have been evaluated, MM remains largely incurable. It is therefore important to further explore the risk factors for disease progression, and to design trials aimed at improving the patient outcomes. Previous studies have considered the presence of a gain in 1q21 as a risk factor for a poorer overall survival. Gain of 1q21 is one of the most common chromosomal aberrations in MM, being detected by fluorescence in situ hybridization in 36% to 47% of newly-diagnosed patients, as well as 52% and 62% patients with relapsed MM. Although a series of reports identified 1q21 gain in MM as a significant and independent poor prognostic factor, other studies failed to demonstrate any prognostic value. Thus, the prognostic value of 1q21 gain in MM remains controversial. We reviewed the current knowledge about 1q21 gain and its value for the clinical management of MM.","PeriodicalId":64349,"journal":{"name":"Journal of Nutritional Oncology","volume":"6 1","pages":"50 - 56"},"PeriodicalIF":0.0,"publicationDate":"2021-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48580876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Multimodal Nutrition Education for Cancer Patients 癌症患者的多模式营养教育

Journal of Nutritional Oncology Pub Date : 2021-05-15 DOI: 10.34175/jno202102002

Yin Feng Li, Li Zhang, X. Xiao, H. Liao, Jing Wang, Xiaoping Tang

引用次数: 1

Combining the Patient-Generated Subjective Global Assessment (PG- SGA) and Objective Nutrition Assessment Parameters Better Predicts Malnutrition in Elderly Patients with Colorectal Cancer 结合患者主观总体评价(PG- SGA)和客观营养评价参数更好地预测老年结直肠癌患者的营养不良

Journal of Nutritional Oncology Pub Date : 2020-01-01 DOI: 10.34175/jno202001003

Wen Jun Wang, Ting Li, Xu Wang, Wei Li, J. Cui

引用次数: 4

Effect of Weight Loss on Survival in Esophageal Cancer Patients undergoing Neoadjuvant Chemoradiotherapy and Surgery 食管癌患者接受新辅助放化疗和手术后体重减轻对生存的影响

Journal of Nutritional Oncology Pub Date : 2020-01-01 DOI: 10.34175/jno202003005

Jia Hua Lyu, Tao Li, Yong Tao Han, Lei Wu, Lin Peng, Qi Feng Wang, L. Liang

引用次数: 0

Microbiota: a Sword that Breaks Through Diabetes 微生物群:突破糖尿病的利剑

Journal of Nutritional Oncology Pub Date : 2020-01-01 DOI: 10.34175/jno202003001

Z. Dai, J. Zhang, Qi Wu, Huiwen Fang, D. Tang, Dao-rong Wang

引用次数: 0

Oncothermia in Combination with Vitamin C Infusion for Non-small Cell Lung Cancer: a Case Report 肿瘤降温联合维生素C输注治疗非小细胞肺癌1例

Journal of Nutritional Oncology Pub Date : 2019-01-01 DOI: 10.34175/jno201903007

Jun Wen Ou, Yi Min Lu, Xin Yu Zhu, Clifford L.K. Pang

引用次数: 0

A Tool for the Treatment of Gastrointestinal Tumors: Micro- Ecological Immunotherapy 治疗胃肠道肿瘤的工具:微生态免疫疗法

Journal of Nutritional Oncology Pub Date : 2019-01-01 DOI: 10.34175/jno201904001

Z. Dai, Qi Wu, J. Zhang, Jia Xu, Hanjian Zhu, Jin Gao, Zhuangzhuang Liu, D. Tang, Dao-rong Wang

{"title":"A Tool for the Treatment of Gastrointestinal Tumors: Micro- Ecological Immunotherapy","authors":"Z. Dai, Qi Wu, J. Zhang, Jia Xu, Hanjian Zhu, Jin Gao, Zhuangzhuang Liu, D. Tang, Dao-rong Wang","doi":"10.34175/jno201904001","DOIUrl":"https://doi.org/10.34175/jno201904001","url":null,"abstract":"to Abstract: It has been proposed that the intestinal Changes in the microbiota can cause dysfunction of the gastrointestinal tract, thereby promoting carcinogenic changes, leading to the occurrence of gastrointestinal tumors. Recent studies on intestinal microbiota have opened up a new area in intestinal micro-ecological immunotherapy. The intestinal microbiota is a double-edged sword. Gut microbes participate in carcinogenesis, but can also be used for immunotherapy. The intestinal microbiota is also regulated by the daily diet. Intestinal micro-ecological immunotherapy combines intestinal immune nutrition and intestinal ecological nutrition to make full use of the intestinal microbiota to strengthen nutritional support. Micro-ecological immunotherapy enhances the body’s immune function by providing energy, improving the functional state of tissues and organs, protecting the intestinal mucosal barrier and maintaining normal intestinal microbiota balance. This involves, to some extent, PD-1 and PD-L1. The microbiota is beneficial to improve the clinical efficacy of conventional anti-cancer therapy and to reduce the incidence of complications. At the same time, micro-ecological immunotherapy is itself active and effective in the perioperative treatment of tumors, which is of great significance for the prognosis of the patient. Gastrointestinal tumors are increasingly linked to intestinal microbiota, and various microbiota-related technologies and drugs have been developed. In the future, the intestinal microbiota may represent a screening marker for gastrointestinal tumors. In addition, clinicians may be able to prevent and treat cancers by changing the gene expression levels of certain microbiota, or by regulating the types of microbes present.","PeriodicalId":64349,"journal":{"name":"Journal of Nutritional Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing the Efficacy of Anti-tumor Immunotherapy by Targeting T Cell Metabolism 靶向T细胞代谢增强抗肿瘤免疫治疗的疗效

Journal of Nutritional Oncology Pub Date : 2019-01-01 DOI: 10.34175/jno201902003

X. Ji, Qiuer Liu

引用次数: 0